- Eliquis sales rose 25% in 3Q.
- Growth was driven by higher U.S. prices.
- Higher global demand also contributed.
Pfizer said third-quarter Eliquis sales rose 25%, helped by higher U.S. prices and stronger global demand. The company is preparing for the blood thinner to lose patent protection.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.